Merck Raises Year View as 3Q Beats, Keytruda, Remicade Miss
Source: BFW (Bloomberg First Word)
Tickers
MRK US (Merck & Co Inc)
JNJ US (Johnson & Johnson)
4508 JP (Mitsubishi Tanabe Pharma Corp)
CSL AU (CSL Ltd)
To de-activate this alert, click here
UUID: 7947283
(Bloomberg) -- Merck & Co. 3Q adj EPS $1.07, est. 99c (range 95c-$1.05); includes 4c-share benefit on timing of shipments in Japan ahead of a resource planning system Merck is implementing in 4Q.
Alert: HALISTER- 3Q rev. $10.5b, est. $10.17b (range $9.85b-$10.49b); includes estimated benefit of $150m of additional sales on Japan shipments timing
- Januvia/Janumet $1.55b, est. $1.62b
- Zetia/Vytorin $944m
- Gardasil/Gardasil 9 $860m
- Proquad/MMR II/Varivax $496m
- Keytruda $356m, est. $371.4m
- Isentress $372m, est. $332m
- Remicade $311m, est. $318.3m; notes declines on European biosimilar competition
- Sees 2016 adj EPS $3.71-$3.78, saw $3.67-$3.77 (July 29), est. $3.75 (range $3.68-$3.79)
- Sees 2016 rev. $39.7b-$40.2b, saw $39.1b-$40.1b (July 29), est. $39.66b (range $39.18b-$40.08b)
- Call 8am 877-381-5782, pw 8756137; preview
Source: BFW (Bloomberg First Word)
Tickers
MRK US (Merck & Co Inc)
JNJ US (Johnson & Johnson)
4508 JP (Mitsubishi Tanabe Pharma Corp)
CSL AU (CSL Ltd)
To de-activate this alert, click here
UUID: 7947283